LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Accrued Liabilities
$4.3m
CAGR 3-Years
49%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Accrued Liabilities
€1.4m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Accrued Liabilities
$34.2m
CAGR 3-Years
-2%
CAGR 5-Years
15%
CAGR 10-Years
42%
argenx SE
XBRU:ARGX
Accrued Liabilities
$190.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Accrued Liabilities
$38m
CAGR 3-Years
9%
CAGR 5-Years
65%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Accrued Liabilities?
Accrued Liabilities
4.3m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Accrued Liabilities amounts to 4.3m USD.

What is LAVA Therapeutics NV's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
49%

Over the last year, the Accrued Liabilities growth was -45%. The average annual Accrued Liabilities growth rates for LAVA Therapeutics NV have been 49% over the past three years .

Back to Top